152 related articles for article (PubMed ID: 12595968)
1. Long-term calcineurin inhibition and magnesium balance after renal transplantation.
Mazzola BL; Vannini SD; Truttmann AC; von Vigier RO; Wermuth B; Ferrari P; Bianchetti MG
Transpl Int; 2003 Feb; 16(2):76-81. PubMed ID: 12595968
[TBL] [Abstract][Full Text] [Related]
2. Ionised and total serum magnesium in renal transplant patients.
Mazzaferro S; Barberi S; Scarda A; Pasquali M; Rubino F; D'Erasmo E
J Nephrol; 2002; 15(3):275-80. PubMed ID: 12113599
[TBL] [Abstract][Full Text] [Related]
3. Plasma (total and ionized), erythrocyte and platelet magnesium levels in renal transplant recipients during cyclosporine and/or azathioprine treatment.
Allegra A; Corica F; Ientile R; Corsonello A; Sparacino V; Accettola F; Caputo F; Macaione S; Buemi M
Magnes Res; 1998 Mar; 11(1):11-8. PubMed ID: 9595545
[TBL] [Abstract][Full Text] [Related]
4. Impact of calcineurin inhibitors on urinary excretion of mycophenolic acid and its glucuronide in kidney transplant recipients.
Naito T; Mino Y; Otsuka A; Ushiyama T; Ito T; Ozono S; Kagawa Y; Kawakami J
J Clin Pharmacol; 2009 Jun; 49(6):710-8. PubMed ID: 19451405
[TBL] [Abstract][Full Text] [Related]
5. Impact of cyclosporine A on magnesium homeostasis: clinical observation in lung transplant recipients and experimental study in mice.
Sabbagh F; El Tawil Z; Lecerf F; Hulin A; Maurois P; Dartevelle P; Bac P; German-Fattal M
Transplantation; 2008 Aug; 86(3):436-44. PubMed ID: 18698248
[TBL] [Abstract][Full Text] [Related]
6. Changes in oxidative stress in renal graft patients receiving calcineurin inhibitors: cyclosporine versus tacrolimus.
Akbasli AC; Keven K; Erbay B; Nebioglu S
Exp Clin Transplant; 2012 Oct; 10(5):439-45. PubMed ID: 22817282
[TBL] [Abstract][Full Text] [Related]
7. Aldosterone resistance in kidney transplantation is in part induced by a down-regulation of mineralocorticoid receptor expression.
Heering PJ; Kurschat C; Vo DT; Klein-Vehne N; Fehsel K; Ivens K
Clin Transplant; 2004 Apr; 18(2):186-92. PubMed ID: 15016134
[TBL] [Abstract][Full Text] [Related]
8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
[TBL] [Abstract][Full Text] [Related]
9. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
10. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.
Simonson SG; Raza A; Martin PD; Mitchell PD; Jarcho JA; Brown CD; Windass AS; Schneck DW
Clin Pharmacol Ther; 2004 Aug; 76(2):167-77. PubMed ID: 15289793
[TBL] [Abstract][Full Text] [Related]
11. Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients.
Cohen DL; Warburton KM; Warren G; Bloom RD; Townsend RR
Am J Hypertens; 2004 Mar; 17(3):209-12. PubMed ID: 15001192
[TBL] [Abstract][Full Text] [Related]
12. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
Bardet V; Junior AP; Coste J; Lecoq-Lafon C; Chouzenoux S; Bernard D; Soubrane O; Lacombe C; Calmus Y; Conti F
Liver Transpl; 2006 Nov; 12(11):1649-54. PubMed ID: 17058250
[TBL] [Abstract][Full Text] [Related]
13. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
14. Low serum magnesium is associated with decreased graft survival in patients with chronic cyclosporin nephrotoxicity.
Holzmacher R; Kendziorski C; Michael Hofman R; Jaffery J; Becker B; Djamali A
Nephrol Dial Transplant; 2005 Jul; 20(7):1456-62. PubMed ID: 15840674
[TBL] [Abstract][Full Text] [Related]
15. Arterial elasticity measurement in renal transplant patients under anticalcineurin immunosuppression.
Martínez-Castelao A; Sarrias X; Bestard O; Gil-Vernet S; Serón D; Cruzado JM; Moreso F; Díez-Noguera A; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3788-90. PubMed ID: 16386539
[TBL] [Abstract][Full Text] [Related]
16. Tacrolimus-associated hypomagnesemia in renal transplant recipients.
Navaneethan SD; Sankarasubbaiyan S; Gross MD; Jeevanantham V; Monk RD
Transplant Proc; 2006 Jun; 38(5):1320-2. PubMed ID: 16797291
[TBL] [Abstract][Full Text] [Related]
17. Relation of magnesium level to cyclosporine and metabolic complications in renal transplant recipients.
Ahmadi F; Naseri R; Lessan-Pezeshki M
Saudi J Kidney Dis Transpl; 2009 Sep; 20(5):766-9. PubMed ID: 19736470
[TBL] [Abstract][Full Text] [Related]
18. Early short-term profile of serum magnesium concentration in living donor renal transplant recipients on cyclosporine.
Kim HJ; Ahn YH; Kee CS; Lee KS; Kwak JY
Transplant Proc; 1994 Aug; 26(4):2178-80. PubMed ID: 8066713
[No Abstract] [Full Text] [Related]
19. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
Suwelack B; Kobelt V; Erfmann M; Hausberg M; Gerhardt U; Rahn KH; Hohage H
Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus in liver transplant recipients with renal dysfunction offers no advantage over low-dose calcineurin inhibitor regimens.
DuBay D; Smith RJ; Qiu KG; Levy GA; Lilly L; Therapondos G
Liver Transpl; 2008 May; 14(5):651-9. PubMed ID: 18433069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
